|
|
Post by peppy on Oct 4, 2017 18:29:56 GMT -5
|
|
rrb
Newbie
Posts: 1 
|
Post by rrb on Oct 4, 2017 18:40:12 GMT -5
Not even close to competing with Afrezza, not to mention the fact that it still must be injected.
|
|
|
|
Post by peppy on Oct 4, 2017 18:43:58 GMT -5
Not even close to competing with Afrezza, not to mention the fact that it still must be injected. agreed. Take that to the hospital pharmacy assessment board meeting.
(and the fast money half time show)
|
|
|
|
Post by sayhey24 on Oct 4, 2017 19:04:39 GMT -5
Not even close to competing with Afrezza, not to mention the fact that it still must be injected. ... and ALL the injection site issues being reported. Fiasp is just a big mess and IMO DOA. The other thing which often gets lost is afrezza is human insulin. Its the exact same insulin molecule the pancreas makes. Fiasp and all other RAA's are GMO molecules which have been modified for absorption purposes. Whats causing all the injection site issues with Fiasp is probably all the added chemicals to preserve it and make absorption faster. Heck, maybe they would have done better and had less issues if they just added WD-40. For me give me the natural versus the GMO and in this case the natural is so much better its a no-brainer. |
|
|
|
Post by peppy on Oct 4, 2017 19:13:31 GMT -5
hospital pharmacies.
efficacy? the ability to produce a desired or intended result. does it work?
is it safe? minimal refrigeration.
Can the hospital make money on it? per dose, oh yeah.
We get hospitals, Danbury covered? the rest gravy?
I am but a black sheep who has lost my way. I need the finance, business knowledgeable here.
What do you think?
www.screencast.com/t/Q8CeRZDM8
|
|
|
|
Post by peppy on Oct 4, 2017 19:24:37 GMT -5
lilly, sanofi, and Nordisk, Pfizer Ceo's ....what the heck are they thinking?
contracts with these hospitals... hmmm |
|
|
|
Post by sayhey24 on Oct 4, 2017 19:25:29 GMT -5
Peppy - all Mike has to do is close the deals he says he has on the table. Now, today Mike is in a significantly different position than he was last Friday. Everyone wanted a deal done months ago but Mike made the right decision to hold back until he had table 4.
If he closes 3 of the deals MNKD is off to the races. Distributorships require sales quotas and should have required upfront product purchases. Lets hope these have really big initial purchases.
|
|
|
|
Post by peppy on Oct 4, 2017 19:36:56 GMT -5
Peppy - all Mike has to do is close the deals he says he has on the table. Now, today Mike is in a significantly different position than he was last Friday. Everyone wanted a deal done months ago but Mike made the right decision to hold back until he had table 4. If he closes 3 of the deals MNKD is off to the races. Distributorships require sales quotas and should have required upfront product purchases. Lets hope these have really big initial purchases. so the reason for this whip we are/going to witness is financing is arranged. beating down the door.
It has been laid up on our table.
www.screencast.com/t/Q8CeRZDM8
Where is Matt when you need him? 
|
|
|
|
Post by dreamboatcruise on Oct 5, 2017 0:31:46 GMT -5
Peppy - all Mike has to do is close the deals he says he has on the table. Now, today Mike is in a significantly different position than he was last Friday. Everyone wanted a deal done months ago but Mike made the right decision to hold back until he had table 4. If he closes 3 of the deals MNKD is off to the races. Distributorships require sales quotas and should have required upfront product purchases. Lets hope these have really big initial purchases. If you're talking about an international deal, there isn't going to be an immediate order because there would still be long process of getting approval by the state regulatory agency. Can you point to one other deal by any pharma for an international distributor that had a "big initial purchase". Seems unlikely this ever happens. |
|
|
|
Post by ghochr on Oct 5, 2017 5:48:08 GMT -5
Peppy - all Mike has to do is close the deals he says he has on the table. Now, today Mike is in a significantly different position than he was last Friday. Everyone wanted a deal done months ago but Mike made the right decision to hold back until he had table 4. If he closes 3 of the deals MNKD is off to the races. Distributorships require sales quotas and should have required upfront product purchases. Lets hope these have really big initial purchases. If you're talking about an international deal, there isn't going to be an immediate order because there would still be long process of getting approval by the state regulatory agency. Can you point to one other deal by any pharma for an international distributor that had a "big initial purchase". Seems unlikely this ever happens. Anything is possible because he is a Mannkind shareholder and one can dream anything but far from reality. He must still be looking for the 200 mil order of Afrezza from a small country and the ship to UAE. |
|
|
|
Post by lennymnkd on Oct 5, 2017 6:18:27 GMT -5
Not even close to competing with Afrezza, not to mention the fact that it still must be injected. Injected : so yesterday ! |
|
|
|
Post by hammer on Oct 5, 2017 6:22:39 GMT -5
FIASP is the best that BP can come up with and it still does not even come close to benefit and action of AFREZZA.
Watch how fast you start to see television commercials for Fiasp and compare to the excuse why SNY produced zero commercials for Afrezza.
|
|
|
|
Post by peppy on Oct 5, 2017 6:55:20 GMT -5
FIASP is the best that BP can come up with and it still does not even come close to benefit and action of AFREZZA. Watch how fast you start to see television commercials for Fiasp and compare to the excuse why SNY produced zero commercials for Afrezza. Sanofi had the euglycemic clamp studies data prior to contract break. we got the study from Sanofi, June of 2016 www.mannkindcorp.com/Collateral/Documents/English-US/Baughman%20poster%20100-LB%20FINAL%20X2.pdf
The study then used for the label change. 10/1/2017.
The plot thickens. (Fiasp however is www.novonordisk-us.com/) www.screencast.com/t/Q8CeRZDM8
sanofi; Apidra. www.screencast.com/t/XdBezkMs Obesity
Insulin glulisine and regular human insulin were administered subcutaneously at a dose of 0.3 Units/kg in a euglycemic clamp study in obese, non-diabetic subjects (n=18) with a body mass index (BMI) between 30 and 40 kg/m2. The median time to maximum concentration (Tmax) was 85 minutes (range 49 to 150 minutes) and the median peak concentration (Cmax) was 192 microUnits/mL (range 98 to 380 microUnits/mL) for insulin glulisine compared to a median Tmax of 150 minutes (range 90 to 240 minutes) and a median Cmax of 86 microUnits/mL (range 43 to 175 microUnits/mL) for regular human insulin.
The more rapid onset of action and shorter duration of activity of APIDRA and insulin lispro compared to regular human insulin were maintained in an obese non-diabetic population (n= 18). (Figure 4.)
page 15. 
|
|
|
|
Post by hammer on Oct 5, 2017 7:52:01 GMT -5
FIASP is the best that BP can come up with and it still does not even come close to benefit and action of AFREZZA. Watch how fast you start to see television commercials for Fiasp and compare to the excuse why SNY produced zero commercials for Afrezza. Sanofi had the euglycemic clamp studies data prior to contract break. we got the study from Sanofi, June of 2016 www.mannkindcorp.com/Collateral/Documents/English-US/Baughman%20poster%20100-LB%20FINAL%20X2.pdf
The study then used for the label change. 10/1/2017.
The plot thickens. (Fiasp however is www.novonordisk-us.com/) www.screencast.com/t/Q8CeRZDM8
Peppy,
The clamp study is one of few high points in the failed partnership. It was at the request of the FDA, SNY had very little choice not to conduct the study. It would have been an early telltale sign of sandbagging. The study by recollection was conducted in Germany, was this an attempt to perhaps skew results? The delay on TV commercials was IMHO a sandbagging excuse of which I am sure MNKD had big problems with but since complete marketing control was signed over to SNY they could not resist. Toujeo was approved around the same time as AFrezza and SNY marketed to the masses quickly. NVO as well will have TV commercials out soon. So much for the high road of waiting 6 months post approval for television marketing. Afrezza is not the only drug SNY sandbagged. Obviously MNKD believed the monetary recuperation was better than they would have achieved in court. The contract was in the jurisdiction of New York State not France. If MNKD had the financial resources and time they should have brought suit. |
|
|
|
Post by peppy on Oct 5, 2017 8:05:22 GMT -5
in the now, for now;
this is what the physicians and insurance companies have to work with. Ad Nausea,
Apidra (by sanofi)
Insulin glulisine and regular human insulin were administered subcutaneously at a dose of 0.3 Units/kg in a euglycemic clamp study in obese, non-diabetic subjects (n=18) with a body mass index (BMI) between 30 and 40 kg/m2. The median time to maximum concentration (Tmax) was 85 minutes (range 49 to 150 minutes) and the median peak concentration (Cmax) was 192 microUnits/mL (range 98 to 380 microUnits/mL) for insulin glulisine compared to a median Tmax of 150 minutes (range 90 to 240 minutes) and a median Cmax of 86 microUnits/mL (range 43 to 175 microUnits/mL) for regular human insulin.
The more rapid onset of action and shorter duration of activity of APIDRA and insulin lispro compared to regular human insulin were maintained in an obese non-diabetic population (n= 18). (Figure 4.)
|
|
